
Keywords: Multiple sclerosis; Natalizumab; Fingolimod; Disease modifying drugs; Drug Switching; Immunomodulation; PE; primary endpoint; SE; secondary endpoint; REA; recurrent event analysis; PML; progressive multifocal leukoencephalopathy; aPBVC; annualized percent